ReviewFrontiers in pharmacology2023
Drug exposure during pregnancy: Current understanding and approaches to measure maternal-fetal drug exposure.
Review in Frontiers in pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 41 citations in OpenAlex.
- Histoplasmosis in Pregnancy: A Review and Patient Perspective.Open forum infectious diseases · 2026Review
- Effect of Late Second to Early Third Trimester of Pregnancy on the Activity of Renal Organic Anion Transporters (OAT1 and OAT3): A Biomarker Study.Clinical pharmacology and therapeutics · 2026Article
- Recapitulating gestational progression: a high-throughput 3D bioprinted vascularized human placenta demonstrating stage-specific molecular and functional signatures of human pregnancy.Scientific reports · 2026Article
- Review
- Target-Controlled Infusion for Caesarean Delivery Under General Anesthesia: From Conventional Pharmacokinetic Models to Physiologically Based Pharmacokinetic Modeling.Life (Basel, Switzerland) · 2026Review
- Delineating the effects of prenatal oxycodone exposure and melatonin treatment on placental and fetal outcomes in pregnant rats.bioRxiv : the preprint server for biology · 2026Article
- Optimisation of Micronutrient Supplementation During Pregnancy: Interactions Between Bioactive Compounds, Their Impact on Health, and Regulatory Considerations.Biomolecules · 2026Review
- Current approaches and advances in placental toxicology.Trends in endocrinology and metabolism: TEM · 2026Review
- Morphometric-Assisted Prediction of Developmental Toxicity Using Stem Cell-Based Embryo Models in Microwells.Advanced healthcare materials · 2025Article
- Evaluating maternal drug use disparities, risk factors and outcomes in Northeast Arkansas: a pre, during, and post-COVID-19 pandemic analysis.BMC public health · 2025Article
- Review
- An advancement in developmental and reproductive toxicity (DART) risk assessment: evaluation of a bioactivity and exposure-based NAM toolbox.Frontiers in toxicology · 2025Article
- Patterns of prescription, over-the-counter, and herbal medication use among pregnant women in Buraydah, Saudi Arabia: a cross-sectional study.Frontiers in pharmacology · 2025Article
- Oxidative Stress Induced by Antivirals: Implications for Adverse Outcomes During Pregnancy and in Newborns.Antioxidants (Basel, Switzerland) · 2024Review
- Organic Sunscreens and Their Products of Degradation in Biotic and Abiotic Conditions-In Silico Studies of Drug-Likeness and Human Placental Transport.International journal of molecular sciences · 2024Article
- Antiarrhythmic Drug Use in Pregnancy: Considerations and Safety Profiles.Journal of cardiovascular development and disease · 2024Review
- Review
- Fetus Exposure to Drugs and Chemicals: A Holistic Overview on the Assessment of Their Transport and Metabolism across the Human Placental Barrier.Diseases (Basel, Switzerland) · 2024Review
- Relationship between Eating Habits and 4-Nonylphenol Concentration in Breast Milk of Women in Slovakia.Life (Basel, Switzerland) · 2023Article
- Pharmacokinetics and Safety of Group A and B Anti-Tuberculosis Drugs Used in Treatment of Rifampicin-Resistant Tuberculosis during Pregnancy and Post-Partum: A Narrative Review.Pathogens (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
Prescription drug use is prevalent during pregnancy, yet there is limited knowledge about maternal-fetal safety and efficacy of this drug use because pregnant individuals have historically been excluded from clinical trials. Underrepresentation has resulted in a lack of data available to estimate or predict fetal drug exposure. Approaches to study fetal drug pharmacology are limited and must be evaluated for feasibility and accuracy. Anatomic and physiological changes throughout pregnancy fluctuate based on gestational age and can affect drug pharmacokinetics (PK) for both mother and fetus. Drug concentrations have been studied throughout different stages of gestation and at or following delivery in tissue and fluid biospecimens. Sampling amniotic fluid, umbilical cord blood, placental tissue, meconium, umbilical cord tissue, and neonatal hair present surrogate options to quantify and characterize fetal drug exposure. These sampling methods can be applied to all therapeutics including small molecule drugs, large molecule drugs, conjugated nanoparticles, and chemical exposures. Alternative approaches to determine PK have been explored, including physiologically based PK modeling,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.